Junshi Biosciences' Loqtorzi has received MHRA approval for NPC and ESCC, marking the first NPC drug and a PD-L1-independent ...

Keymed Biosciences has licensed global rights for CM336, excluding Greater China, to Platina Medicines in a deal worth up to ...

Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) ...

Amferia's peptide-based hydrogel boosts antibiotic effectiveness by up to 64 times against resistant bacteria, stabilizing ...

US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study ...

Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark ...

In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, ...

Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 Dec.

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License ...

Orano Med, a subsidiary of the Orano Group, has begun construction of an Advanced Thorium Extraction Facility (ATEF) in ...

Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which ...

US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...